Dendritic Cell Hyperactivation via TLR Ligands and Inflammasome Lipids
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer immunotherapy approaches lack diversity and are insufficient in inducing adaptive immune responses against tumors resistant to PD-1 inhibition, particularly in enhancing T helper type I and cytotoxic T lymphocyte responses.
Innovation Solution
Administering a combination of Toll-Like Receptor (TLR) ligands, non-canonical inflammasome-activating lipids, and cancer immunogens, such as tumor lysates, to hyperactivate dendritic cells, promoting TH1 and CTL responses without inducing TH2 immunity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current cancer immunotherapy approaches are used, then treatment simplicity is maintained, but the ability to induce adaptive immune responses against tumors resistant to PD-1 inhibition is insufficient
Solution Approach 1:
The patent segments the immunotherapy approach into three distinct functional components: (1) TLR ligands that activate pattern recognition receptors on dendritic cells, (2) non-canonical inflammasome-activating lipids that trigger inflammasome pathways, and (3) cancer immunogens that provide tumor-specific antigens. This segmentation allows each component to perform its specific function optimally while collectively inducing robust adaptive immune responses against tumors resistant to PD-1 inhibition.
Solution Approach 2:
The patent employs a composite immunotherapy formulation combining multiple types of immunomodulatory agents (TLR ligands, inflammasome-activating lipids, and cancer immunogens) into a unified therapeutic approach. This composite strategy synergistically activates multiple dendritic cell signaling pathways simultaneously, creating a enhanced immune response that overcomes tumor resistance mechanisms that would block single-modality therapies.
2Reliability
If dendritic cells are hyperactivated to induce strong TH1 and CTL responses, then protective immunity against tumors is enhanced, but the risk of inducing unwanted immune activation or side effects increases
Solution Approach 1:
The patent applies local quality by directing immune activation specifically at dendritic cells through targeted receptor-ligand interactions. The TLR ligands bind to specific pattern recognition receptors on DCs, the inflammasome-activating lipids trigger pathways predominantly in antigen-presenting cells, and the cancer immunogens provide tumor-specific antigens. This localized activation at the dendritic cell level ensures potent TH1 and CTL responses while minimizing off-target immune activation and systemic side effects.
Data Source
AI summary
The present application is related to cancer immunotherapy, e.g. stimulation of T cell mediated anti-tumor therapy. Accordingly, described herein are methods of inducing or enhancing an adaptive immune response to a cancer in a subject and methods of treating cancer in a subject. In some embodiments, the methods hyperactivate dendritic cells (DCs), which induce T helper type I (TH1) and cytotoxic T lymphocyte (CTL) responses in the absence of TH2 immunity.